Urology

  • DESMOMELT®
    DESMOMELT®
    (desmopressin)
    (desmopressin)

    MINIRIN(R)

    Urology
  • DesmoMelt(R) (desmopressin)

    DesmoMelt® (desmopressin)

    DesmoMelt® is indicated for the treatment of primary nocturnal enuresis (PNE) in patients aged 5-65 years.

    Desmopressin is the active ingredient in DesmoMelt®. Desmopressin is a synthetic analogue of naturally occurring vasopressin which increases the concentration of urine at night, thereby preventing the bladder from getting as full. It is important that children suffering with bedwetting are diagnosed early and are offered an appropriate treatment intervention. Self-esteem is improved by treatment in young children so early intervention is recommended.

    In the UK, 500,000 children aged between 5 and 16 regularly wet the bed but for most children, something can be done to help manage or resolve bedwetting.

    Find out more information at www.stopbewetting.org

    For specific product information please consult the summaries of product characteristics (SPC): www.medicines.org.uk/emc/medicine/17268

     

    Other forms of desmopressin available at Ferring:

    Desmotabs® are indicated for primary nocturnal enuresis

    For specific product information please consult the summaries of product characteristics (SPC): www.medicines.org.uk/emc/medicine/662

    DDAVP Melt is indicated for the treatment of vasopressin-sensitive cranial diabetes insipidus or in the treatment of post-hypophysectomy polyuria/polydipsia.

    For specific product information please consult the summaries of product characteristics (SPC): www.medicines.org.uk/emc/medicine/17265

    DDAVP® Tablet is indicated for the treatment of vasopressin-sensitive cranial diabetes insipidus or in the treatment of post-hypophysectomy polyuria/polydipsia.

    For specific product information please consult the summaries of product characteristics (SPC):

     

    DDAVP® Tablets 0.1mg: www.medicines.org.uk/emc/medicine/4217

    DDAVP® Tablets 0.2mg: www.medicines.org.uk/emc/medicine/658

    DDAVP®/Desmopressin Injection is indicated as follows:

    1) Diagnosis and treatment of cranial diabetes insipidus.

    2) To increase Factor VIII:C and Factor VIII:Ag in patients with mild to moderate haemophilia or von Willebrand's disease undergoing surgery or following trauma.

    3) To establish renal concentration capacity.

    4) To treat headache resulting from a lumbar puncture.

    5) To test for fibrinolytic response.

    For specific product information please consult the summaries of product characteristics (SPC): www.medicines.org.uk/emc/medicine/659

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advise on medical issues please consult your doctor. All information on this site is intended for UK audiences only.

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard and also to Ferring Pharmaceuticals Telephone: 08449310050 and Email: medical@ferring.com. By reporting side effects you can help provide more information on the safety of this medicine.

     

    18 Jun 2015                                                   GEN/1078/2015/UK

  • FIRMAGON®
    FIRMAGON®
    (degarelix)
    (degarelix)

    Urology
  • FIRMAGON® (degarelix)

    Firmagon® is a gonadotrophin releasing hormone (GnRH) antagonist indicated for treatment of adult male patients with advanced hormone-dependent prostate cancer. Hormone dependent prostate cancer is a type of cancer that grows by using the testosterone in the body. It works by directly blocking the message from the brain that tells the testes to produce testosterone, thereby stopping the signal that is making the cancer cells grow and divide.

    For specific product information please consult the summaries of product characteristics (SPC) from the following links:

    FIRMAGON 120 mg powder and solvent for solution for injection: www.medicines.org.uk/emc/medicine/21701

    FIRMAGON 80 mg powder and solvent for solution for injection: www.medicines.org.uk/emc/medicine/21686

     

     

     

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advise on medical issues please consult your doctor. All information on this site is intended for UK audiences only.

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard and also to Ferring Pharmaceuticals Telephone: 08449310050 and Email: medical@ferring.com. By reporting side effects you can help provide more information on the safety of this medicine.

     

    18 Jun 2015                                                   GEN/1078/2015/UK

     

     

  • TESTIM®
    TESTIM®
    (testosterone)
    (testosterone)

    Urology
  • TESTIM® (testosterone)

    Testim® is a testosterone replacement therapy indicated for for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests. It works by replacing or supplementing the testosterone that is naturally made in the body.

    Testim® is prescribed in 5g tubes and should be applied once a day, at about the same time each day, to clean, dry, intact, skin of the shoulders and/or upper arms. It is preferable that the gel is applied in the morning. For patients who wash in the morning, Testim® should be applied after washing, bathing or showering. Patients should thoroughly wash their hands immediately with soap and water after Testim® has been applied. After application of Testim®, patients should allow the gel to dry for a few minutes and then dress with clothing that covers the application sites.

    Find out more at www.menshealthmatters.org

    For specific product information please consult the summaries of product characteristics (SPC): www.medicines.org.uk/emc/medicine/22159

     

     

     testim couple.jpg

    Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of Ferring UK. For advise on medical issues please consult your doctor. All information on this site is intended for UK audiences only.

    Reporting of side effects

    If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard and also to Ferring Pharmaceuticals Telephone: 08449310050 and Email: medical@ferring.com. By reporting side effects you can help provide more information on the safety of this medicine.

     

    18 Jun 2015                                                   GEN/1078/2015/UK

UK office

Ferring Pharmaceuticals Ltd.
Drayton Hall, Church Road, West Drayton.
UB7 7PS

Telephone : +44(0)8449310050

Contact

Global Locator

Corporate Global Locator

You are now leaving www.Ferring.co.uk , a website of Ferring Pharmaceuticals Ltd UK. Links to all outside websites are provided as a resource to our visitors. Ferring Pharmaceuticals Ltd accepts no responsibility for the content of other websites.